• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Where is everyone going?

Quote
















The exodus began in 2018 and will continue. Horrible managers on the MS side, unattainable goals in a crowded market, lack of a pipeline, an Alzheimers drug they are trying to grift past the FDA with suspect data and horrible toxic home office leadership..... what's here to stay for?? Too many great opportunities in the industry right now to stay on a sinking ship....
 




anonymous said:
The exodus began in 2018 and will continue. Horrible managers on the MS side, unattainable goals in a crowded market, lack of a pipeline, an Alzheimers drug they are trying to grift past the FDA with suspect data and horrible toxic home office leadership..... what's here to stay for?? Too many great opportunities in the industry right now to stay on a sinking ship....
Click to expand...
2018? More like 2015......
 












Top Bottom
Back
Quote